Zacks Research Estimates Pfizer's FY2025 Earnings (NYSE:PFE)

Pfizer Inc. (NYSE:PFE - Free Report) - Investment analysts at Zacks Research boosted their FY2025 EPS estimates for shares of Pfizer in a research note issued to investors on Tuesday, January 21st. Zacks Research analyst K. Shah now expects that the biopharmaceutical company will earn $2.89 per share for the year, up from their previous estimate of $2.86. The consensus estimate for Pfizer's current full-year earnings is $2.94 per share. Zacks Research also issued estimates for Pfizer's Q4 2025 earnings at $0.85 EPS, Q3 2026 earnings at $0.88 EPS, Q4 2026 earnings at $0.86 EPS and FY2026 earnings at $3.00 EPS.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion during the quarter, compared to analysts' expectations of $14.92 billion. During the same period in the prior year, the company posted ($0.17) earnings per share. The company's revenue for the quarter was up 31.2% compared to the same quarter last year.

A number of other research firms have also weighed in on PFE. Evercore ISI raised Pfizer to a "strong-buy" rating in a research note on Wednesday, October 30th. Cantor Fitzgerald restated an "overweight" rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. StockNews.com cut shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, November 20th. Truist Financial dropped their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. Finally, Bank of America reiterated a "neutral" rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $32.00.

Pfizer Price Performance

PFE stock traded up $0.45 during trading on Thursday, reaching $26.46. The company's stock had a trading volume of 40,939,261 shares, compared to its average volume of 35,118,707. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company's fifty day moving average is $26.07 and its 200-day moving average is $27.96. The company has a market capitalization of $149.94 billion, a P/E ratio of 35.75, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. Pfizer has a 1 year low of $24.48 and a 1 year high of $31.54.

Hedge Funds Weigh In On Pfizer

Several hedge funds have recently bought and sold shares of PFE. Retirement Wealth Solutions LLC purchased a new stake in shares of Pfizer in the fourth quarter valued at approximately $26,000. Gladius Capital Management LP lifted its holdings in shares of Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 38,015 shares during the period. Quarry LP bought a new position in shares of Pfizer during the 2nd quarter worth $31,000. Teachers Insurance & Annuity Association of America purchased a new position in shares of Pfizer during the third quarter valued at $35,000. Finally, Joseph Group Capital Management lifted its stake in Pfizer by 168.3% in the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company's stock worth $36,000 after acquiring an additional 771 shares during the period. Institutional investors own 68.36% of the company's stock.

Insider Buying and Selling

In other news, Director Scott Gottlieb acquired 1,000 shares of the firm's stock in a transaction on Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is owned by corporate insiders.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.50%. The ex-dividend date is Friday, January 24th. This is a positive change from Pfizer's previous quarterly dividend of $0.42. Pfizer's dividend payout ratio is presently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.